Codexis, Inc. (CDXS)

NASDAQ: CDXS · IEX Real-Time Price · USD
3.490
-0.020 (-0.57%)
At close: Mar 28, 2024, 4:00 PM
3.495
+0.005 (0.14%)
After-hours: Mar 28, 2024, 7:16 PM EDT
-0.57%
Market Cap 246.77M
Revenue (ttm) 70.14M
Net Income (ttm) -76.24M
Shares Out 70.30M
EPS (ttm) -1.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 435,172
Open 3.540
Previous Close 3.510
Day's Range 3.450 - 3.719
52-Week Range 1.450 - 4.910
Beta 2.04
Analysts Strong Buy
Price Target 7.50 (+114.9%)
Earnings Date May 2, 2024

About CDXS

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used f... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 22, 2010
Employees 174
Stock Exchange NASDAQ
Ticker Symbol CDXS
Full Company Profile

Financial Performance

In 2023, Codexis's revenue was $70.14 million, a decrease of -49.39% compared to the previous year's $138.59 million. Losses were -$76.24 million, 127.0% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CDXS stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 114.90% from the latest price.

Price Target
$7.5
(114.90% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway...

4 weeks ago - GlobeNewsWire

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive...

4 weeks ago - GlobeNewsWire

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care...

4 weeks ago - GlobeNewsWire

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Board expertise encompasses oligonucleotide research, development, manufacturing and commercialization to support development of ECO Synthesis™ manufacturing platform Board expertise encompasses oligo...

5 weeks ago - GlobeNewsWire

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth qua...

6 weeks ago - GlobeNewsWire

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Term loan agreement enables Company to accelerate development and enhance commercialization of  ECO Synthesis™ manufacturing platform for RNAi therapeutics

6 weeks ago - GlobeNewsWire

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

TnX transposase development collaboration leverages strengths of both companies TnX transposase development collaboration leverages strengths of both companies

2 months ago - GlobeNewsWire

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs Company to retain economic interest in biotherapeutic asset while remo...

3 months ago - GlobeNewsWire

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Deal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymes Deal creates strategic collaboration to enable more efficient R...

3 months ago - GlobeNewsWire

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13,...

3 months ago - GlobeNewsWire

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8, 2023,...

3 months ago - GlobeNewsWire

Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focuse...

4 months ago - GlobeNewsWire

Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference

REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler Health...

4 months ago - GlobeNewsWire

Codexis Reports Third Quarter 2023 Financial Results

Company Remains on Track to Demonstrate Gram-Scale Synthesis with ECO Synthesis™ Platform for RNAi Therapeutics Production by End of Year

5 months ago - GlobeNewsWire

Codexis to Participate in Upcoming Healthcare Conferences

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in four upcoming investor c...

5 months ago - GlobeNewsWire

Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe

REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approac...

5 months ago - GlobeNewsWire

Codexis to Report Third Quarter 2023 Financial Results on November 2

REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quar...

5 months ago - GlobeNewsWire

Codexis CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award

REDWOOD CITY, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced President and Chief Executive Officer Stephen Dilly, MBBS, ...

6 months ago - GlobeNewsWire

Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award

REDWOOD CITY, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced Stephen Dilly, MBBS, PhD, President and Chief Executive Off...

6 months ago - GlobeNewsWire

Codexis to Participate in Cantor Global Healthcare Conference

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Cantor Global Healthcare Confer...

7 months ago - GlobeNewsWire

Codexis Announces Agreement for Assignment and Assumption of San Carlos Facility Lease

Assignment results in estimated cumulative cash savings of more than $30M and supports projected cash runway to mid-2026 Assignment results in estimated cumulative cash savings of more than $30M and s...

7 months ago - GlobeNewsWire

Codexis Reports Second Quarter 2023 Financial Results

Company Recently Announced Enhanced Strategic Focus and Portfolio Prioritization Anticipate Demonstrating Gram-Scale Synthesis of ECO Synthesis™ Technology for RNAi Therapeutics Production by End of Y...

8 months ago - GlobeNewsWire

Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics

New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape

8 months ago - GlobeNewsWire

Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026

Organization Streamlined to Focus on Continued Advancement and Commercialization of ECO Synthesis™ Platform for RNAi Therapeutics Production

9 months ago - GlobeNewsWire

Codexis Announces New Employment Inducement Grants

REDWOOD CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to four new employees as appro...

10 months ago - GlobeNewsWire